logo
Plus   Neg
Share
Email

Edwards Lifesciences Backs FY17 View, Sees Higher FY18; To Buy Back $1 Bln Share

Edwards Lifesciences Corp. (EW), a company in patient-focused innovations for structural heart disease and critical care monitoring, Thursday said it reaffirmed

For fiscal 2017, the company still expects adjusted earnings per share of $3.65 to $3.85, and global sales at the high end of $3 billion to $3.4 billion target, representing underlying growth of 10 to 11%.

On average, analysts polled by Thomson Reuters expect earnings of $3.75 per share on sales of $3.39 billion for the year. Analysts' estimates typically exclude special items.

For fiscal 2018, the company expects adjusted earnings per share of $4.10 to $4.30, and global sales of $3.5 to $3.9 billion, representing underlying growth of 9 to 10%.

Analysts expect earnings of $4.15 per share on sales of $3.71 billion for the year.

The company expects 2018 THVT sales of $2.1 to $2.4 billion, representing underlying growth of 11% to 15%.

The company will discuss its strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance during its annual investor conference today in New York City.

Michael Mussallem, chairman and CEO, said, "In 2018, we are projecting strong financial results while we continue to invest aggressively to provide breakthrough therapies for patients in need. During the year, we expect to achieve a number of meaningful clinical milestones that will serve as indicators of our progress in advancing multiple transcatheter mitral and tricuspid programs."

Separately, Edwards Lifesciences announced that its Board of Directors recently authorized a new share repurchase program to acquire up to an additional $1 billion of the company's outstanding common shares.

The company also announced that in November it entered into an accelerated share repurchase agreement to acquire $150 million of Edwards' common stock.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
German investor confidence rose strongly in December, defying expectations for a modest weakening, but caution prevailed as financial analysts' assessment of the current economic situation again deteriorated sharply due to sluggish economic growth and uncertainties linked to global trade and Brexit. The ZEW Indicator of Economic Sentiment for Germany rose 6.6 points to reach minus 17.5 points. After moving sharply lower in morning trading, stocks staged a substantial turnaround over the course of the trading session on Monday. The major averages climbed well off their worst levels of the day and into positive territory. Despite recently calling this year's $716 billion defense budget "crazy," President Donald Trump reportedly plans to ask for a sharp increase in military spending next fiscal year.
Follow RTT